Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 3, pp 455–462 | Cite as

Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan

  • Mohammad Ismail
  • Zafar IqbalEmail author
  • Muhammad Bilal Khattak
  • Muhammad Imran Khan
  • Hassan Arsalan
  • Arshad Javaid
  • Qamar Gul
  • Faramoz Khan
Research Article

Abstract

Background Multiple drugs therapies may be the potential source of drug–drug interactions that can result in alteration of therapeutic response and/or increase untoward effects of many drugs. Objective To identify the frequency and levels of potential drug–drug interactions (pDDIs) in internal medicine wards and their association with patients’ age, gender, length of hospital stay and number of prescribed medications; and to describe management of frequently identified major or moderate pDDIs. Setting Internal medicine wards of two major tertiary care hospitals of Khyber Pakhtunkhwa, Pakistan. Method Micromedex Drug-Reax system was used to screen patient’s profiles for pDDIs. Logistic regression was applied to determine the odds ratio for specific risk factors of pDDIs i.e., age, gender, hospital-stay and number of medications. Main outcome measure Overall prevalence and prevalence of contraindicated, major, moderate and minor pDDIs; levels of pDDIs; frequently identified major or moderate interactions; and odds ratios for risk factors. Results Total, 188 interacting drug-combinations were identified that contributed to 675 pDDIs. Of 400 patients, 52.8 % patients were presented with at least one pDDI (overall prevalence), 21.3 % with at least one major-pDDI, and 44.3 % with at least one moderate-pDDI. Of 675 pDDIs, most were of moderate (63.6 %) or major severity (23 %); good (61.2 %) or fair (25.5 %) type of scientific evidence; and delayed onset (50.2 %). Most frequently identified major or moderate interactions resulted in 45.3 % of all pDDIs. Their potential adverse outcomes included hepatotoxicity, bleeding, ototoxicity, nephrotoxicity, hypoglycemia, hyperglycemia, risk of thrombosis, hypotension, cardiac arrhythmias and reduction in therapeutic-effectiveness. There was significant association of the occurrence of pDDIs with patients’ age of 60 years or more (OR = 2.1; 95 % CI = 1.3–3.3; p = 0.003), hospital stay of 6 days or longer (OR = 2.6; 95 % CI = 1.5–4.5; p = 0.001), and seven or more number of prescribed medications (OR = 5.9; 95 % CI = 3.6–9.6; p < 0.001). Conclusion The present study has recorded a high prevalence of pDDIs in internal medicine wards. Patients with old age, longer hospital stay and increased number of prescribed medications were at higher risk.

Keywords

Adverse drug interaction Clinical pharmacy Drug related problem Pakistan Potential drug–drug interaction Prescriptions screening 

Notes

Acknowledgments

We are very grateful to administration, consultants and all other staff of Ayub Teaching Hospital, Abbottabad and Khyber Teaching Hospital, Peshawar, for administrative support; and Dr. Jibran Hasan Khan and Mr. Abdul Majid, for help in data collection. We wish to thank Mr. Sadeeq-Ur-Rahman, PhD student, Molecular Microbiology Department, Free University Amsterdam, the Netherlands, for reviewing the English grammar of the manuscript. .

Funding

The authors are very thankful to University of Peshawar for financial support.

Conflicts of interest

None to declare.

References

  1. 1.
    Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, Spanakis M, et al. Potential drug–drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci. 2010;32:187–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Zwart-van-Rijkom JEF, Uijtendaal EV, Ten Berg MJ, Van Solinge WW, Egberts ACG. Frequency and nature of drug–drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68:187–93.PubMedCrossRefGoogle Scholar
  5. 5.
    van den Bemt PM, Egberts AC, Lenderink AW, Verzijl JM, Simons KA, van der Pol WS, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22:62–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407.PubMedCrossRefGoogle Scholar
  8. 8.
    Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med. 2008;19:413–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Anonymous. Report of the Health System Review Mission—Pakistan. Islamabad: World Health Organization, 2007.Google Scholar
  10. 10.
    Creese A, Gasman N, Mariko M. The world medicines situation: World Health Organization, 2004.Google Scholar
  11. 11.
    Ismail M, Iqbal Z, Hammad M, Ahsan S, Sheikh AL, Asim SM, et al. Drug utilization evaluation of piperacillin/tazobactam in a tertiary care teaching hospital. Healthmed. 2010;4:1044–55.Google Scholar
  12. 12.
    Khan FA, Hoda MQ. Drug related critical incidents. Anaesthesia. 2005;60:48–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Nishtar S. Pharmaceuticals–strategic considerations in health reforms in Pakistan. J Pak Med Assoc. 2006;56:S100–11.PubMedGoogle Scholar
  14. 14.
    Babar ZU, Jamshed S. Social pharmacy strengthening clinical pharmacy: why pharmaceutical policy research is needed in Pakistan? Pharm World Sci. 2008;30:617–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Ismail M, Iqbal Z, Khattak MB, Javaid A, Khan MI, Khan TM, et al. Potential drug–drug interactions in psychiatric ward of a tertiary care hospital: prevalence, levels and association with risk factors. Trop J Pharm Res. 2012;11:289–96.CrossRefGoogle Scholar
  16. 16.
    Micromedex Drug-Reax® System. [database on CD-ROM].Volume 150. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. 2011.Google Scholar
  17. 17.
    Tatro D, editor. Drug interaction facts: facts and comparisons. St. Louis: Wolters Kluwer Health; 2009.Google Scholar
  18. 18.
    Ibanez A, Alcala M, Garcia J, Puche E. Drug-drug interactions in patients from an internal medicine service. Farm Hosp. 2008;32:293–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Egger SS, Drewe J, Schlienger RG. Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–8.PubMedGoogle Scholar
  20. 20.
    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600.PubMedCrossRefGoogle Scholar
  21. 21.
    Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Doubova SV, Reyes-Morales H, Torres-Arreola LdP, Suarez-Orteg M. Potential drug–drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res. 2007;7:147.CrossRefGoogle Scholar
  23. 23.
    Baxter K, editor. Stockley’s drug interactions. 9th ed. London: Pharmaceutical Press; 2010.Google Scholar
  24. 24.
    Hansten PD, Horn JR, editors. Drug interactions analysis and management: St. Louis: Wolters Kluwer Health Inc.; 2008.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Mohammad Ismail
    • 1
  • Zafar Iqbal
    • 1
    Email author
  • Muhammad Bilal Khattak
    • 2
  • Muhammad Imran Khan
    • 2
  • Hassan Arsalan
    • 3
  • Arshad Javaid
    • 4
  • Qamar Gul
    • 5
  • Faramoz Khan
    • 6
  1. 1.Department of PharmacyUniversity of PeshawarPeshawarPakistan
  2. 2.Ayub Teaching HospitalAyub Medical CollegeAbbottabadPakistan
  3. 3.Department of PharmacySarhad University of Science and Information TechnologyPeshawarPakistan
  4. 4.Post Graduate Medical Institute (PGMI)Lady Reading Hospital (LRH)PeshawarPakistan
  5. 5.Department of PharmacyUniversity of MalakandChakdaraPakistan
  6. 6.Medical-B UnitKhyber Teaching HospitalPeshawarPakistan

Personalised recommendations